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a  b  s  t  r  a  c  t
Background:  Dyspepsia  represents  a symptom  domain  rather  than  a diagnostic  condition  and  covers  a
wide  range  of  complex,  underlying  pathophysiologies  that are  not  well  understood.  The  review  explores
comparative  effectiveness  interventions  for  the  treatment  of  symptomatic  dyspepsia  along  a  pragmatic-
explanatory  continuum.  The  aim is  to  identify  relevant  design  characteristics  applicable  to future upper
gastrointestinal  comparative  effectiveness  research  employing  integrative  medicine.
Methods:  Medline,  CINAHL,  Scopus,  Cochrane  Central  Register  of Controlled  Trials  (CENTRAL)  and  WHO
Clinical  Trials  were  systematically  searched  until  January  2019.  Included  articles  were  original  research
with two  or more  comparative  intervention  arms  for the  primary  outcome;  relief  of symptomatic  dys-
pepsia. Evaluation  of the  studies  was  conducted  using  the  pragmatic-explanatory  continuum  indicator
summary  (PRECIS-2)  tool.
Results:  Thirty-six  articles  were  included  in the  review.  A total  of  68  Patient  Reported  Outcome  Measure-
ments  (PROMs),  utilizing  50 different  formats  were  deployed  across  the studies.  The  appraisal  process
revealed  eligibility,  flexibility  in  adherence,  flexibility  in  delivery  and  organization  domains  further
aligned  towards  an  explanatory  design.
Conclusion:  This review  identified  three  design  characteristics  relevant  for  future  comparative  effective-
ness  research  for the treatment  of  upper  gastrointestinal  disorders  in a community  setting.  Extensive
exclusion  eligibility  criteria  limited  the  generalization  of  comparative  effectiveness  study  results  by
removing  sub-groups  of  the  target  populations  more  at risk  of  dyspeptic  symptoms.  The  requirement
for  entry  endoscopy  was  found  to be common  and not  always  pragmatically  justifiable.  Development
of  validated  PROMs  appropriate  for a  generic  application  to  upper  gastrointestinal  disorders  would  be
advantageous  for future  comparative  effectiveness  research  within  integrative  medicine.
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1. Introduction
Symptomatic dyspepsia encompasses a wide range of upper gas-
trointestinal (GIT) symptoms and overlapping GIT conditions.1–5
Broadly, dyspepsia is defined as any symptom referable to the upper
gastrointestinal tract, including heartburn, reflux, upper abom-
inable or epigastric pain or discomfit.6 This definition captures
variations in terminology, diagnostic criteria and unclassified pre-
sentation of symptoms as would be encountered in a community
setting. Despite symptoms of dyspepsia being reported by 20.8% of
the global population the underlying pathophysiologies are com-
∗ Corresponding author at: Australian Research Centre in Complementary and
Integrative Medicine, Faculty of Health, University of Technology Sydney, 15 Broad-
way, Ultimo, NSW, 2007, Australia.
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lex and not well understood.3,4 Pathologies which may result in
yspepsia can include undetected chronic Helicobacter pylori infec-
ion, peptic ulcer disease, gastric malignancy, duodenal mucosal
nflammatory and permeability changes.3,7 Preliminary research
uggests 25% of individuals experience an overlap between both
yspepsia and gastrooesophageal reflux symptoms.8 Symptoms of
yspepsia may  fluctuate over time, aging and with lifestyle factors.9
nteractions between the GIT and the brain can result in individuals
ith dyspepsia experiencing increased anxiety and depression,7,10
eductions in work productivity, and compromised quality of life.11
n the United States of America, management of dyspepsia is esti-
ated to cost health services over $US 18 billion per annum.11
Globally, approximately only 40% of patients with symptomatic
yspepsia utilise a primary health provider for assistance and 15%
f these will be referred for secondary care.3 Clinical management
or uninvestigated dyspepsia can include initial treatment with a
















































N. Elliott, A. Steel, B. Leech et al. 
proton-pump inhibitor (PPI),3,12 despite emerging evidence of PPI
ingestion being associated with renal, cardiovascular, gastrointesti-
nal, autoimmune and neurologic adverse effects.13 Complementary
medicine (CM) - a diverse group of non-conventional medical
and health practices used together with conventional medical
care 14 - is also currently used for the symptomatic treatment
of dyspepsia.15,16 It has been reported more than 50% of those
experiencing functional gastrointestinal disorders seek CM in the
community setting for the management of their condition.15 In
Australia, a recent study reported 63.5% of those with a diag-
nosed gastrointestinal disease use CM products and 48.1% have
visited a CM practitioner for gastrointestinal (GIT) assistance.16
The World Gastroenterology Organisation recommends the use of
locally available symptomatic remedies for GERD if they are safe,
effective and less costly than prescription medications in areas with
limited resources.17 Conversely, the American College of Gastroen-
terology and the Canadian Association of Gastroenterology has
recommended CM is not used for dyspepsia as there is no clear evi-
dence for their effectiveness.3 To address this discrepancy, research
is needed that is appropriately designed to evaluate the effective-
ness of complementary medicine compared to other commonly
available, and frequently prescribed, treatments.9
The heterogeneity of dyspepsia pathophysiology and symp-
tomatology presents obstacles for effective research and clinical
management. Classic biomedical research is built upon assessment
of efficacy under ideal or controlled conditions.18 Yet, the more the
research design imposes controls on subject selection, eligibility
and participation, the greater the risk the results will not apply to
the management of dyspepsia among the broader population.18,19
An alternative approach is Comparative Effectiveness Research
(CER). CER is the direct comparison of existing health care inter-
ventions to determine which treatment works best, for whom,
and under which context.20 Correspondingly, CER is designed to
support a health care provider make an informed decision on the
most effective treatment option for their patient’s symptoms and
resources.18,19 An important aspect of CER is the concept of prag-
matic trials: the interventions are tested in routine, usual care
settings.21 This type of approach lends itself to research examining
CM treatments for dyspepsia being undertaken in a CM practitioner
setting. CM practitioners commonly utilize health care interven-
tions with a long history of traditional use, which continue to be
prescribed in contemporary practice. The intention of this review is
to explore pragmatic design characteristics relevant for future CER
of CM treatments available to those seeking relief of upper gastroin-
testinal disorders in a community setting, including undiagnosed
and unclassified dyspepsia.
2. Methods
The literature review protocol was developed and implemented
using the Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015 statement.22 The protocol has
been submitted and registered with the International Prospec-
tive Register of Systematic Reviews and registration (PROSPERO)
(#CRD42020127885).
2.1. Study aimThe systematic review aims to explore the design characteristics
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.2. Search strategy
The following databases were searched: MEDLINE; CINAHL;
COPUS; Cochrane Central Register of Controlled Trials (CENTRAL)
nd WHO  Clinical Trials. Date range was January 2014 to January
019. Medical subject headings and existing literature reviews8,23
ere used to help formulate the following search term strat-
gy: (“dyspepsia” OR “heartburn” OR “gastroesophageal reflux” OR
GERD” OR “GORD” OR “NERD” OR “gastroesophageal-reflux dis-
ase” OR “gastrointestinal reflux disease” OR “non-erosive reflux
isease” OR “gastro esophageal reflux disease” OR “nonerosive
sophagitis” OR “endoscopically negative reflux disease”) AND
“treatment” OR “intervention” OR “comparative”).
.3. Eligibility criteria
Included articles were original research with two or more com-
arative intervention arms for the relief of symptomatic dyspepsia.
rticles were included if the subjects were over 18 years old, human
nd the primary treatment aim was  relief of symptomatic dys-
epsia. Articles were excluded for: no comparative intervention
rm; intervention compared with placebo; treatment of helicobac-
er pylori intervention arm; or, if an intervention was surgical. No
anguage restrictions were applied.
.4. Study selection
All identified citations were downloaded to Endnote. After
emoval of duplicates, the remaining citations were screened by
itle, abstract and full-text against the eligibility criteria by one
esearcher (NE) (Fig. 1).24 In accordance with the AMSTAR 2
ppraisal tool for systematic reviews, a sample of eligible studies
20%) was  reviewed by one other researcher (BL).25
.5. Data extraction
Data from those studies in English language or translated via
oogle translation were independently extracted by one researcher
NE) and reviewed by two  other researchers (BL and AS). Data from
he eight Mandarin manuscripts were independently extracted via
 fourth researcher (WP). The data was reviewed and incorporated
nto the systematic literature review by researcher (NE). Extracted
nformation consists of: authors, publishing date, country, study
esign and interventions. Additional extracted information was
ormatted according to PRECIS -2 domain design categories: eli-
ibility, recruitment, setting, organization, flexibility: delivery,
exibility: adherence, follow-up, outcome and primary analysis
Table 1).
.6. Data extraction process
The criteria used to extract information for the nine PRECIS-2
omain categories were conducted in accordance with the pub-
ished methodology, with a number of clarifications.26 Setting
ncluded location of measurements, participant testing and place of
reatment intervention. It is assumed participants ingest oral inter-
entions within their community setting and return to their site of
ecruitment for outcome measurements unless specified. Valida-
ion status of Patient Reported Outcome Measurements (PROMs)
as extracted from a systematic review on gastroesophageal reflux
isease questionnaires.23.7. Methodology for exclusion categories
Exclusion criteria were categorized into; alarm symptoms,
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BDI: d 0, 28, 56
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n  = 175
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n analyzed = 32
Patients excluded:
Non-compliance

















































n analyzed = 75
Patients excluded:
























































more than 1 wk
Measurements:
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n  = 60










































































































































































































n  = 59
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GSS: d 0, 14, 28





































































n analyzed = 80
Adverse events:
Unspecified
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To what extent are
all data included?



















































































































GSRS: d 0 to 56,
wk  16, 24, 32
(unclear)
VAS: d 0 to 56,











Phase 1: n = 53, n
analyzed = 45
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FSSG score: d 0,
28
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Acu, acupuncture; AE, adverse effects; AR, adverse reactions; AT, Acupuncture Treatment; BDI, Beck Depressive Inventory; bds, twice daily; BMI, Body Mass Index; CSR, Complete Symptom Resolution; DSSS, dyspeptic symptom
sum  score; ECG, electrocardiogram; ED, emergency department; FD, functional dyspepsia; FD-QOL, Functional Dyspepsia-Related Quality of Life; FSSG, Frequency Scale for the Symptoms of GERD; GERD, gastroesophageal reflux
disease;  GERD-Q, Gastroesophageal Reflux Disease Questionnaire; GIT, gastrointestinal tract; GP general practitioner; GOS, Global Overall Symptom; GSRS, Gastrointestinal Symptom Rating Scale; GSS, General Symptom Score;
HADS,  Hospital Anxiety and Depression Scale; h.pylori, helicobacter pylori; IV, intravenous; LPR, laryngopharyngeal reflux; MSS, Major Symptom Score; NA, not applicable; NDI, Nepean Dyspepsia Index; NDI-K, Nepean dyspepsia
index  - Korean; OTE, overall treatment effect; PPI, proton pump inhibitor; PRO, patient reported outcomes; PSQI, Pittsburgh Sleep Quality Index; QoL, quality of life; RDQ, Reflux Disease Questionnaire; RQS, Reflux Quality Score;
RSI,  reflux symptom index; SAS, Self-Rating Anxiety Scale; SDS, Self-Rating Depression Scale; SF-12, Short Form 12 Health Survey; SF-LDQ, Short-Form Leeds Dyspepsia Questionnaire; STAI, State-Trait Anxiety Inventory; tds,
three  times daily; qad, every other day; qds, four times daily; VAS, visual analogue scale.
17


























Fig. 1. Preferred Reporting Items for Systematic reviews and Meta Analyses (PRISM
included in the final systematic literature review.
Syndrome (IBS), GIT conditions, GIT surgery, lifestyle, medications
and others (Table 2). The number of defined items listed within each
category is identified. Details of exclusions categorized as ‘other’ are
stated in the comments section.
2.8. Evaluation of studies against PRECIS-2 domains
As the focus for this review is to explore design characteristics
of comparative effectiveness trials for symptomatic dyspepsia and
not their clinical decision; the risk of bias was not assessed. Instead,
an appraisal was conducted utilizing the PRECIS-2 tool (Table 3).26
Although this tool was originally designed to assist in the construc-
tion of trials, more recently it has been used as a tool for assessment
of trial design characteristics.19,27,28 Furthermore, evaluation of
studies against PRECIS-2 domains may  uncover significant, domain
specific factors and highlight important subgroup considerations,
relevant for future comparative effectiveness research design.19,27
The methodology for the appraisal process followed previous pub-
lished research.19 A phase of calibration to ensure consistency in
scoring across each PRECIS-2 domain occurred between the three
researchers (NE, BL and AS) before commencement. A score of over
three was classified as a pragmatic approach using an approach
adopted by previous research.26,27 A domain score was left blank
if there was insufficient information in the article to inform the
scoring process.
3. Results
Primary search returned 7879 articles (Fig. 1). After excluding
duplicates (n = 1728), 6151 studies were screened by title / abstracts
and 90 articles selected for further assessment. Of those articles, 54
were excluded: symptomatic dyspepsia improvement was not the
primary endpoint (n = 7), study protocol (n = 4), registered clinical




18w diagram. Starting with 7879 citations identified in the database, 36 articles were
lacebo treatment arm (n = 8), observation report (n = 3), duplicate
n = 2) and translation with the web-based interface; ‘Google Trans-
ation’, was  unsuccessful (n = 2).29,30
.1. Study characteristics
Table 1 shows extracted data from the 36 studies. Thirty
wo were randomised and31–62 thirteen studies were open-
abel.33,36,38,40,42–44,46–48,53,63,64 The sample size ranged from 32
o 464 participants (mean = 98). One study did not list the sam-
le size and the author has been contacted.33 Two studies were
n pregnant women.39,46 Included studies were conducted across
4 countries within the following World Health Organisation
egions: Eastern Mediterranean (n = 7),31,34,42,43,46,50,54 Western-
acific region (n = 20),35,36,38–41,44,49,52,53,55–61,62,63,65 South-East
sia (n = 6)32,39,47,48,51,64 and Europe (n = 3).33,45,66 Treatment
uration ranged from one day45 to 24 months63 (mean = 50
ays). Nineteen studies employed complementary medicine
nterventions; plant medicines (n = 11),31,32,34,42,43,46,50,54,57,60,63
cupuncture (n = 5),35,37,55,56,61 breathing exercises (n = 2)33,65 and
igestive enzymes (n = 1).62
.2. PRECIS-2 Eligibility – who is selected to participate in the trial
Many participants were required to pass one or more
astrointestinal inclusion criteria assessments; endoscopy
n = 23),31–36,38,40,41,44,49,51–60,64,65 Rome diagnostic criteria for
unctional Dyspepsia (FD) (n = 8),31–37,47 gastrointestinal symptom
core patient questionnaires (n = 10)37,38,40,44,45,49,57,64–66 and /
r biological measurements (n = 7).33,35,52,55,56,59,65 Two  stud-
es required participants to be pregnant.39,46 Six studies required
articipants to be under 66 years of age (n = 9).31,43,48,50,54,56,57,60,65
There were 390 reported eligibility exclusion criteria across













































Iran 1 3 – 3 1 5 3 1 2 – 19 History of reflux
disease excluded




Eherer  2014 Austria – – 1 – – 1 – – – – 2 –
Hosseini  et al.
2018
Iran – 6 – 1 1 3 – 1 1 – 13 Excluded if history
of smoking
Jin  et al. 2015 China – 2 – 3 – – – – 4 – 9 –
Kamiya  et al.
2017
Japan – 8 2 3 – – 1 1 3 1 19 Other: alcohol or
substance abuse




Liang  et al.
2017
Taiwan – 3 1 2 – 1 1 – 1 – 9 GIT  conditions:
peptic ulcer disease


























Mizuki  et al.
2016





Nie  & Song
2015



















































Japan – 2 2 1 – 2 1 – 4 1 13 Other: abnormal
lab values
Panahi  et al.
2015





Panahi  et al.
2016




Saifullah  et al.
2018
Bangladesh – 3 1 2 – 7 – – 4 1 18 Other: debilitated
patient
Sakurai  et al.
2018






GIT  meds 8wks
prior to onset
Senay  et al.
2016
Turkey – – 2 2 – – – – 1 1 6 –
Setright  R 2017 Australia – – – – – – – – 2 – 2 –
Shakeri  et al.
2018





Shen  et al. 2014 China Unspecified
Singh  et al.
2015












































Sri roja et al.
2017
India – – 1 3 – 1 – – – – 5 Exclude; complex
ulcer
Takenaka  et al.
2016




Toseef  et al.
2015
Pakistan – 3 – – – – – – – – 3 –
Vedamanickam
et  al. 2017





Wang  et al.
2014
China – 2 1 1 – 2 1 – 2 – 9




– – – – – – – – – – – Exclusions not
specified
Yamaji  et al.
2014















Ye  & Wei  2015 China Unspecified
Zhang  et al.
2017
China 1 2 – – – 1 1 – – – 5
Zohalinezhad
et  al. 2016







Total:  8 81 22 53 6 49 14 9 42 16 299
Eligibility exclusion criteria as described in the studies were categorized into 10 groups.
Contra-indications to treatment included intolerance to the intervention medication.
Demographic included age, women of reproductive age, non-pregnant women, pregnancy and lactation.
Each co-morbidity detailed in the study was counted as one item in the co-morbidity category.
Each medication group was  counted as one item under the medications category.
Each GIT condition described in the study was  counted as one item for this category, excluding IBS.






















Critical appraisal summary table using PRECIS-2 domain scores.
PRECIS-2 Domain Score















Sakurai et al. 2018 1 4 4 2 2 2 2 2 3 2.44 2.37 E
Wang  et al. 2014 2 3 5 1 2 2 2 – 5 2.75 2.43 E
Yang  et al. 2015 2 4 5 1 2 1 1 5 1 2.33 2.5 E
Jin  et al. 2015 2 1 5 2 2 3 2 2 3 2.44 2.62 E
Mizuki  et al. 2016 1 3 5 3 3 2 2 2 4 2.77 2.62 E
Choi  et al. 2015 1 3 5 3 2 2 3 2 4 2.77 2.62 E
Liang  et al. 2017 2 3 4 2 3 2 2 3 5 2.88 2.62 E
Liu  et al. 2017 1 3 5 1 1 1 5 4 5 2.88 2.62 E
Singh  et al. 2015 3 3 3 2 2 3 2 3 5 2.89 2.63 E
Takenaka et al. 2016 2 3 5 2 3 2 2 3 5 3 2.75 E
Azimi  et al. 2017 1 3 4 3 4 2 3 2 5 3 2.75 E
Hosseini et al. 2018 1 4 5 2 3 2 2 3 5 3 2.75 E
Eherer  2014 4 – 3 2 3 2 3 – 4 3 2.83 E
Kamiya  et al. 2017 2 3 5 3 3 2 3 2 5 3.11 2.87 E
Panahai et al. 2015 2 3 5 – 4 2 3 2 5 3.25 3 P
Yamaji  et al. 2014 2 3 4 3 3 2 4 3 5 3.22 3 P
Oshima  et al. 2018 2 4 4 3 3 1 3 4 5 3.22 3 P
Yang  2014 1 5 5 3 2 2 1 5 4 3.11 3 P
Ko  et al. 2016 2 2 5 2 3 4 2 3 4 3 3.12 P
Ong  et al. 2018 1 5 5 2 3 2 2 5 5 3.33 3.12 P
Zohalinezhad et al. 2016 2 3 3 3 3 4 3 4 5 3.33 3.13 P
Vedamanickam et al. 2017 2 4 3 3 4 – – – 3 3.17 3.17 P
Panahai et al. 2016 2 3 5 4 4 4 3 2 5 3.5 3.28 P
Shakeri  et al. 2018 3 4 5 4 4 2 3 2 5 3.55 3.37 P
Li  & Bai 2018 2 4 5 1 2 4 5 4 5 3.44 3.37 P
Meteerattanapipat & Phupong 2017 5 3 5 4 4 2 2 4 5 3.78 3.63 P
Senay  et al. 2016 4 5 5 4 2 – 3 4 5 4 3.86 P
Zhang  et al. 2017 2 5 5 5 1 3 5 5 4 3.88 3.87 P
Toseef  et al. 2015 4 3 5 4 4 4 4 4 5 4.11 4 P
Wilkie  et al. 2018 3 5 5 4 5 3 4 3 5 4.11 4 P
Ye  & Wei  2015 2 4 5 3 – 4 5 5 2 3.75 4 P
Nie  & Song 2015 1 5 5 3 – 4 5 5 5 4.12 4 P
Saifullah et al. 2018 3 5 5 4 5 4 4 5 4 4.22 4.12 P
Sri  Roja et al. 2017 5 3 4 4 4 4 4 5 4 4.11 4.12 P
Shen  et al. 2014 5 5 5 3 – 3 5 5 5 4.5 4.42 P
Setright 2017 4 5 5 5 3 4 5 5 5 4.56 4.5 P
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(Table 2). History of GIT surgery was a cause for exclusion across
fifteen of the included articles.31,32,36,38,40,41,44,49,52–55,59,62,65
Exclusion due to GIT co-morbidities encompassed: IBS
(n = 6),31,32,34,37,42,43 treatment resistant GERD (n = 3),34,40,43
history of reflux disease (n = 2),32,37 maldigestion (n = 2),37,43 gas-
tritis as primary symptom with concurrent antacid use (n = 1),44
gastric or duodenal ulcer on long-term PPI (n = 1),51 Helicobacter
pylori treatment in the past three months (n = 1)40 and heartburn
as primary symptom (n = 1).32
Other causes for exclusion were; reproductive women who
may  fall pregnant (n = 3 ),32,36,54 abnormal laboratory findings
(n = 2),53,54 history of smoking (n = 1),34 childhood illness (n = 1),54
extreme body mass index (n = 1),65 night-shift worker (n = 1)40 and
illiterate (n = 1).45
3.3. PRECIS-2 Recruitment - how are participants recruited into
the trial?
Participants were recruited from patient visit to
hospital (n = 28),31,32,34–38,40–45,47–52,55–60,64,65,67 medical
college (n = 2)51,53 or specialist community based clinic
(n = 13)32,34,36,39,40,44,46,49,50,52,63,64,66 or both. Method of
recruitment; unspecified (n = 15),32,33,36,40,42–44,46–52,63 invita-
tion (n = 6),37–39,41,53,65 advertising (n = 3),35,37,56 consecutive
patients presenting for care (n = 3)64–66 and convenience sampling
(n = 1).34
3.4. PRECIS-2 Setting - where is the trial being done?
Screening and initial prescription phase occurred in
specialist clinics (n = 11),32,34,36,39,40,44,46,49,50,63,66 hospital
(n = 23),36–38,40–45,47–49,51,55–62,64,65 and university departments
(n = 3).33,53,54 Treatment intervention occurred in; community
settings (n = 24),31–34,36–44,46,47,49–54,63,65,66 acupuncture clinic
(n = 2)35,37 and hospital setting (n = 2).45,48 The setting of Patient
Response to Outcome Measurements (PROMs) was unclear. One
study conducted PROMs by phone call and postal questionnaire.66
3.5. PRECIS-2 Organisation-What expertise and resources are
needed to deliver the intervention?
Endoscopy was required in 23
studies.31–36,38,40,41,44,49,51–60,64,65 The studies did not specify
how the endoscopies were performed. An endoscopy involves
the passing of a camera on a lighted tube into the body to pro-
vide a direct view of internal organs while a patient is sedated.68
Although, a variety of novel endoscopic techniques and equipment,
including video capsule endoscopy (VCE) have also emerged.69
In Australia, specialised medical and nursing staff, facilities,
endoscopic equipment, accessories, sterilization, monitoring and
resuscitation equipment must all meet a minimum standard.70
Other medical procedures and expertise required among the
studies included blood tests (n = 10),35,38,41,47,49,50,53,56,59 mea-
surement of peristalsis amplitude of the esophagus (n = 1),52 ECG
(n = 1),47 esophageal manometry and 24 -h pH/impedance mea-
surement testing (n = 2),33,65 and additional training (n = 3).33,37,56
3.6. PRECIS-2 Flexibility: delivery - how should the intervention
be delivered?
Method of delivery was presented as usual care with a
structured protocol for dose, duration and frequency of inter-
vention (n = 26).31–34,36–44,46,48–54,63–67 A wash-out period was
required in ten studies.31–34,36,44,54–56,60 One study described flex-
ibility in selection of acupuncture points for the individual.37
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articipants.63 Alternatively, one study amended the herbal decoc-
ion intervention formula in response to the participant’s changing
ymptoms.60 Ten studies specified lifestyle modifications dur-
ng intervention period; no smoking (n = 4),47,52,59,60 no GI meds
n = 6),31,44,56,59,60,62 no alcohol (n = 4),47,52,59,60 diet improvement
n = 5)37,46,59,60,66 and psychological counselling (n = 1).59
.7. PRECIS-2 Flexibility: adherence -What measures are in place
o make sure the participants adhere to the intervention?
Study design encouraging adherence involved; more than
ne follow-up visit to the study site for participant response
easurements (n = 15),31–36,38,40,42–44,46,49,52,65 exclusion for
on-compliance (n = 14),31,32,35–42,44,46,50,53 counting medications
n = 3),36,39,41 and daily diaries (n = 3).38,39,41
.8. PRECIS-2 follow-up: how closely are participants
ollowed-up?
A total of 68 Patient Reported Outcome Measure-
ent (PROMs), utilizing 50 different formats were applied
mong the 36 studies. Among the outcome measure-
ent instruments there were: disease-specific symptom
ssessments,31,35,37–44,47,52–54,56,57,65,66 customised composite
ymptom questionnaires,32–35,39,41,46,48,50,51,63 quality of life
QoL) surveys32,33,35,37,39,40,59,65 gastrointestinal-generic symp-
om assessments,36,48,49,53,54,60–62,64 visual analogue scales
VAS),34,39,45,49,65 overall treatment effect surveys,32,40,44 cultural
daptations of the Nepean Dyspeptic Index (NDI),32,35,37 daily
iary formats,38,39,41 psychological health questionnaires,35,37,65
omplete symptom resolution surveys,38 patient satisfaction
urvey,64 sleep quality index score55 and a diet diary.38 The
alidated gastrointestinal-generic instrument; Gastrointesti-
al Symptom Rating Scale (GSRS) was the most frequent
nstrument employed (n = 4).36,49,53,54 A mixture of validated
nd unvalidated PROMs was the most popular approach
n = 15).31,32,35,38,39,41,44,48,49,53–57,65 Biological measurements
ere employed across six studies.33,35,37,47,52,58
There was  variability in the frequency of measurement time-
oints during the study period. Follow-up patient response
utcome measurements were taken at the following intervals;
aily (n = 6)32,34,38,39,41,49 one week (n = 8),34,36,38,40,41,44,45,49
wo  weeks (n = 14),31,32,34,36,39–42,44,46,49,52,58,64 four
eeks (n = 21),31–37,40,42,44,46–49,51–54,59,61,65 eight weeks
n = 5)31,37,49,50,52 or longer (n = 8).34,35,49,51,60,63,65,66 Four studies
ere two weeks or less in duration.38,39,41,45
.9. PRECIS-2 Outcome: how relevant is it to participants?
Improvement of symptoms was a primary outcome across all
tudies in accordance with the inclusion criteria for this review. The
valuation of clinical efficacy of intervention was  listed as a subse-
uent primary outcome for two studies48,63 Secondary outcomes
ncluded: QoL (n = 7),32,33,35,37,39,40,44 biomedical measurements
n = 4),33,35,37,52 clinical efficacy (n = 1),49 side effects (n = 2),59,62
atient satisfaction (n = 1)64 and pregnancy outcomes (n = 1).39
.10. PRECIS-2 Primary analysis: to what extent are all data
ncluded?Participants were excluded from primary analy-
is for: non-compliance (n = 14),31,32,35–42,44,46,50,53 lost
o follow-up (n = 8),32,44,46,47,49,53,54 withdrew con-
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(n = 7),31,32,40,43,46,53,55 non-responders (n = 2),34,66 incorrect
diagnosis (n = 1).45
3.11. Evaluation of studies against PRECIS-2 domains
The outcomes of the appraisal process are reported in (Table 3).
Eligibility criteria for inclusion in the review required the primary
treatment aim was relief of symptomatic dyspepsia. Accordingly,
the PRECIS-2 domain, ‘Primary outcome’ received a score of 4.39
out of 5, a very pragmatic result, illustrating the outcome, symptom
improvement replicates a usual care context.
In contrast, the PRECIS-2 domains; ‘eligibility’ (score = 2.33),
‘flexibility in adherence’ (score = 2.65), ‘organization’ (score = 2.82)
and ‘flexibility in delivery’ (score = 2.97) were aligned to an explana-
tory research design.26 An explanatory design will often select for
ideal patients, is highly controlled for an intervention,71,72 and will
generally require more resources than usual care.
A score of 3.0 is considered an equally pragmatic and explana-
tory score.26,27 The mean PRECIS-2 score for the trials was 3.22,
(SD 0.61) indicating the included papers for comparative effective-
ness trials incorporated a distribution of pragmatic and explanatory
design characteristics.
4. Discussion
This review provides an overview of methodological strengths
and weakness of published comparative effectiveness trials for
symptomatic dyspepsia and provides a number of insights to the
design of future trials, particularly for researchers examining CM
interventions.
4.1. Exclusion criteria
The extensive application of exclusion criteria notably affected
the pragmatic ranking of the trials utilizing a PRECIS-2 assess-
ment. Many of the exclusion criteria removed participants with
clinical features linked to a higher incidence of dyspepsia. These
clinical features include; IBS,1 GERD,8 gastritis,12 heartburn,1,3
non-steroidal anti-inflammatory drug use,4 older than 60 years;3
reproductive females,4 mental health co-morbidities9 and history
of GIT surgery.73 The justification for these exclusions was rarely
described and excluding such conditions may  hinder CM prac-
titioners whose patient population is characterised by a greater
proportion of women,74 GIT,16 mental health co-morbidities75
and chronic, complex conditions.16 For example, no included arti-
cles justified the rationale for IBS exclusion. Prior research has
shown IBS patients have a lower resting pressure of the lower
oesophageal sphincter,1 hyperalgesia of the oesophagus76 and 50%
of IBS patients have pathologic reflux.1 It has been reported partic-
ipants with overlap in dyspepsia and IBS may  represent those with
more severe symptom manifestations.2
The studies on pregnant women39,46 employed pre-trial lifestyle
modifications and those who improved were excluded. This
approach is prescriptive and may  or may  not reflect usual care
in Iran46 and Thailand,39where the studies were conducted. The
exclusion represents a loss of informative data and it remains
unknown if a relapse occurred. A separate study excluded partic-
ipants from follow-up if they did not improve.34 It is problematic
to exclude for lifestyle criteria such as drinking alcohol,47,52,59,60
strong tea,52 smoking,47,52,59,60 and ‘bad living habits’,37,60 as
it remains unknown if these sub-groups will be responsive to
the intervention. There are some instances where exclusions
may  be justified, for example, GIT surgery causing anatomi-
cal changes affecting intervention efficacy65 or a participant on
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ent intervention. However, extensive exclusion criteria have the
otential to limit trial findings to a subset of the dyspeptic popula-
ion.
Previous research comparing trial designs has concluded
xplanatory trials, when grouped and analysed together, regularly
eport larger effect sizes than similar pragmatic trials.27 The mea-
ured efficacy of one intervention in a homogenised sample may  be
iluted once applied to the general population experiencing these
ymptoms. Ideally, a pragmatic approach would limit exclusions
o specific contra-indications and include all participants in pri-
ary analysis to enhance transferability of outcomes to a real-life
ontext. This would require increased organisation, collection and
eporting of participant information to account for the myriad of
ndividual variables observed in usual care. Further incorporation
f pragmatism may  benefit future CM research. Pragmatic design
rovides an opportunity to incorporate patient demographics and
o-morbidities common in CM practice. This may  provide further
nsight into the comparative effectiveness of different interven-
ions, and which of those are better suited to a heterogeneous
r subset population group. Admittedly, relaxation of the condi-
ion of entry and extension of the target population would allow
any variables to enter the study and influence results. These fac-
ors would need to be taken into account and results cautiously
nterpreted.
.2. Endoscopy as inclusion criteria
This review identified endoscopy as a common eligibility
equirement in comparative effectiveness research for the treat-
ent of symptomatic dyspepsia. Some included papers employed
ome inclusion criteria, which require an upper endoscopy to
iagnose FD, although, past popularity of the Rome criteria as
 diagnostic and clinical trial tool has been questioned.2,3 A
ecent review demonstrated only 54% of clinical trials strictly
dhered to the Rome eligibility inclusion criteria.77 Additionally,
n participants with FD, endoscopy does not quantify symptom
everity, frequency or impact of the symptoms on the individual.
t has been reported, for some individuals, there is no association
etween symptom severity and endoscopic findings.3,78 Moreover,
ndoscopy is not required for diagnosis or commencement of treat-
ent for symptomatic dyspepsia,17 however, its inclusion may  be
onsidered pragmatic when applied as usual care, based on the
ocio-cultural context of the healthcare policy and the studied
opulation. Recent guidelines for the management of dyspepsia
ecommend the use of endoscopic investigation in patients who
eport alarm features and; or are over 60 years of age.3 Within
he included studies, the majority of participants were under 65
ears of age or excluded if presenting with alarm features. Entry
ndoscopy as a trial requirement is costly,12 disadvantageous for
esearchers with limited resources and access to medical expertise
nd excludes participant groups unwilling to undergo endoscopy.79
n endoscopy is relevant if seeking to classify a condition, iden-
ify physiological change such as mucosal erosion, or aligns with
outine clinical care and characteristics of the studied population.
or instance in Japan, an endoscopic investigation may be a jus-
ifiable component of a pragmatic trial design, due to a higher
ncidence of gastric cancer, resource allocation and recommenda-
ion for this procedure in real-world settings.12,17 A pragmatic trial
esign, authentic to sample populations, genotypes, cultural, geo-
raphical and resource differences is better equipped to reproduce
ntervention results in a real-world context. A pragmatic design
eflective of usual care offers researchers an opportunity to provide
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4.3. Instruments of measurement
No single common tool or methodology was identified among
the included studies to measure patient outcomes for dyspep-
sia. Similarly, this finding has been noted in prior published
research.23,73,77,80 To illustrate, a recent review identified 65 ques-
tionnaires in use for the assessment of symptoms and outcome
measures in GERD intervention trials alone.73
This review evaluated comparative intervention studies for
symptomatic dyspepsia that encompassed various conditions
including FD, dyspepsia, belching, heart-burn, gastritis, GERD, ero-
sive esophagitis, duodenal ulcer, gastric ulcer, IBS and non-erosive
reflux disease. This has contributed to the multiple PROMs observed
in the results but does not fully explain the diversity observed. For
instance, within any given condition, an assortment of PROMs was
employed. A broader international movement towards develop-
ment of meaningful, standardised Core Outcome Measurements in
Effectiveness Trials (COMET) through expert consensus has yet to
decide on a universal set of measures for dyspepsia.81
More specifically, there exists no preferred, single, validated
patient reported outcome tool to measure symptom change
and furthermore, research on methodological aspects of PROMs
development for dyspepsia symptoms is minimal.80 A consensus
statement on clinical trial design for GERD stated PROMs should
be in electronic format, to increase ease of use, reduce the need
for return follow-up assessment and minimise bias.73 Pictograms
have been promoted as a tool to assist symptom identification
overcoming the potential for misunderstanding the terminology
by participants.82 This would also prevent participant exclusion
based on literacy as occurred in one of the included studies.45 The
challenge for future research is to develop a validated PROM tool
which captures symptom improvement across a heterogeneous
population and does not become overly cumbersome for a partici-
pant to complete, leading to increased risk of drop-off. The lack of
consensus on a validated PROM instrument hinders the ability to
effectively compare interventions between research trials.
4.4. Limitations
This study has several limitations. Variations in standard care
practice across regional and socioeconomic lines, created chal-
lenges with maintaining consistency in the PRECIS-2 evaluation
process. For example, endoscopy could be classified as explana-
tory or pragmatic, dependent upon the chosen scope defining
usual care.12,83–85 Furthermore, PRECIS-2 assessors were required
to be familiar with routine care practice across fourteen countries.
Consequently, a potential deficit in their knowledge may  affect
accuracy of the pragmatic score for trial design. Missing or unclear
data items within the included articles may  have affected consis-
tent assessment and calculation of PRECIS-2 summary scores. Two
articles were unable to be translated and could not be included
in the results.29,30 Lastly, design characteristics were assessed for
their pragmatism and not their effect on statistical analyses or trial
results.
4.5. Future directions
This review uncovered several insights relevant for future CER,
in the treatment of upper gastrointestinal conditions. Further
investigation into the influence of eligibility requirements on the
studied population and trial results is warranted. Does requirement
for endoscopy affect study recruitment and introduce a selection
bias into the study design? For instance, a study on the prevalence
and impact of IBS and dyspepsia in China reported 67.3% of par-
ticipants refused to undergo an endoscopy.79 Furthermore, does
the exclusion of age, lifestyle habits, common co-morbidities and
D
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linical features linked to a higher incidence of dyspepsia affect
esults and subsequently health care provider decisions upon an
ppropriate treatment for their patient?
Development of standard, validated PROMs appropriate for a
eneric application to upper gastrointestinal disorders would ben-
fit comparative research in a community setting. Specifically, a
ragmatic PROM tool focussed on patient outcomes and symptom
mprovement, which is simple to use and encompasses overlapping
astrointestinal conditions and a variety of presenting symptoms.
 potential add-on is the inclusion of patient satisfaction as a
easurement outcome,64 and incorporation of electronic data col-
ection formats with pictograms to increase participant adherence
nd reduce the need for return to study site.
Future research into pragmatic design characteristics would
enefit from inclusion of published study protocols to provide
urther details about trial design, and clear categorisation of the
isease group and local standard of care, to minimise variables
nd help clarify the effectiveness of a intervention in a real-world,
ontext.
.6. Conclusion
This review identified three key design characteristics pertinent
or future comparative effectiveness research for the treatment
f upper gastrointestinal disorders. Extensive exclusion eligibil-
ty criteria limits the generalization of comparative effectiveness
tudy results by removing sub-groups of the target populations
ore at risk of dyspeptic symptoms. An ongoing lack of consensus
n a validated measurement tool for patient reported outcomes
n symptomatic dyspepsia was reflected in the multiple PROMs
tilized by the included studies. The trial requirement for entry
ndoscopy was  common; however a majority of sufferers do not
eek treatment for their dyspepsia from their primary healthcare
rovider. In this context, the pragmatic justification for endoscopy
s an eligibility requirement to commence treatment will dif-
er across socio-cultural characteristics, their preferred treatment
athway and the country’s healthcare policy.
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